Helus Pharma Shareholders Overwhelmingly Approve Name Change and…

Event summary

Helus Pharma's shareholders approved all resolutions at the September 22, 2026 annual meeting, including the appointment of Zeifmans LLP as auditor and setting the board size to eight directors.
The name change from Cybin Inc. to Helus Pharma Inc. was approved with 99.315% of votes, effective October 1, 2026.
All director nominees were elected, though Paul Glavine, Michael Halstead, Freda Lewis-Hall, and Eric So received significant withheld votes (28.376% to 28.679%).
63.58% of total shares were represented at the meeting, with 46,452,598 common shares voting.

The big picture

Helus Pharma's name change and governance adjustments reflect its pivot from a clinical-stage biotech to a commercial-ready pharmaceutical player. The overwhelming shareholder approval underscores investor confidence in the company's strategic direction, though the significant withheld votes for some directors highlight potential governance tensions. The shift aligns with broader industry trends toward specialized serotonergic treatments for mental health conditions, a market poised for growth as regulatory pathways for novel therapies expand.

What we're watching

Governance Dynamics: How the significant withheld votes for four directors may impact board cohesion and strategic decision-making.
Commercial Readiness: Whether the name change and governance adjustments signal a successful transition from clinical-stage to commercial-ready pharmaceutical operations.
Regulatory Progress: The pace at which Helus Pharma advances its Breakthrough Therapy Designation candidates (HLP003 and HLP004) through late-stage trials.